Pulse Biosciences CS (PLSE)

$17.61 -0.03 (-0.17%)
Market Cap 1.08B
Revenue (ttm) 0.00
Net Income (ttm) -42.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 92,500
Avg Vol 174,014
Day's Range N/A - N/A
Shares Out 61.52M
Stochastic %K 14%
Beta 1.84
Analysts Strong Buy
Price Target $5.00

Latest News on PLSE

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 7 days ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 10, 2025, 8:00 AM EST - 10 days ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 9:00 AM EST - 17 days ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Dec 23, 2024, 4:30 PM EST - 4 weeks ago

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Dec 19, 2024, 8:00 AM EST - 4 weeks ago

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Dec 17, 2024, 8:00 AM EST - 4 weeks ago

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Oct 31, 2024, 2:25 PM EDT - 2 months ago

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 9:42 PM EDT - 2 months ago

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 4:05 PM EDT - 2 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Oct 30, 2024, 4:02 PM EDT - 2 months ago

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 3 months ago

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 6:50 PM EDT - 5 months ago

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 5 months ago

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Aug 12, 2024, 4:01 PM EDT - 5 months ago

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Aug 8, 2024, 8:00 AM EDT - 5 months ago

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Aug 1, 2024, 4:05 PM EDT - 6 months ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Jul 29, 2024, 4:05 PM EDT - 6 months ago

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Jul 8, 2024, 8:00 AM EDT - 7 months ago

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Jul 3, 2024, 2:44 PM EDT - 7 months ago

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Jun 28, 2024, 8:00 AM EDT - 7 months ago

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Jun 4, 2024, 8:00 AM EDT - 8 months ago

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

May 20, 2024, 4:05 PM EDT - 8 months ago

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

May 16, 2024, 8:00 AM EDT - 8 months ago

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Pulse Biosciences Enhances Executive Leadership Team

May 14, 2024, 4:05 PM EDT - 8 months ago

Pulse Biosciences Enhances Executive Leadership Team

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:29 PM EDT - 9 months ago

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

May 9, 2024, 8:00 AM EDT - 9 months ago

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 9 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

May 2, 2024, 8:00 AM EDT - 9 months ago

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Apr 24, 2024, 4:05 PM EDT - 9 months ago

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:52 PM EDT - 10 months ago

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Mar 28, 2024, 4:12 PM EDT - 10 months ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Mar 28, 2024, 4:10 PM EDT - 10 months ago

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Mar 14, 2024, 4:05 PM EDT - 11 months ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Mar 8, 2024, 1:17 PM EST - 11 months ago

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Feb 14, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Jan 31, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Jan 2, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Dec 20, 2023, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

Nov 21, 2023, 8:00 AM EST - 1 year ago

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 15, 2023, 4:05 PM EST - 1 year ago

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 6:16 PM EST - 1 year ago

Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

Nov 10, 2023, 4:56 PM EST - 1 year ago

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

Oct 30, 2023, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study

Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

Pulse Biosciences' First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Pulse Biosciences' First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting

Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase

Sep 7, 2023, 4:05 PM EDT - 1 year ago

Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase